The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis
| Autor: | Xiu-Ping Luo, Yan-Long Yang, Lei Xian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Lung Neoplasms Epidemiology medicine.medical_treatment Cancer Treatment non-small cell lung cancer (NSCLC) lcsh:Medicine Tubulin Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Odds Ratio Medicine and Health Sciences lcsh:Science Multidisciplinary Hazard ratio Vinorelbine Prognosis Chemotherapy regimen Vinblastine Treatment Outcome Research Design Physical Sciences Taxoids Statistics (Mathematics) medicine.drug Research Article Bridged-Ring Compounds medicine.medical_specialty Clinical Research Design Subgroup analysis Research and Analysis Methods Internal medicine medicine Genetics Humans Statistical Methods Genetic Association Studies Chemotherapy Taxane business.industry Pharmacoepidemiology lcsh:R Biology and Life Sciences Human Genetics Odds ratio medicine.disease Surgery lcsh:Q Clinical Medicine business Publication Bias Mathematics Meta-Analysis |
| Zdroj: | PLoS ONE, Vol 9, Iss 4, p e93997 (2014) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Background A number of studies have examined the relationship between the expression of the class III β-tubulin (TUBB3) and the treatment responses to the taxane/vinorebine-based chemotherapy in patients with non-small cell lung cancer (NSCLC). However, the results of these studies were inconsistent and inconclusive. Therefore, we conducted an up-to-date meta-analysis to evaluate the prognostic role of TUBB3 in the taxane/vinorebine-based chemotherapy. Methods A literature search for relevant studies was conducted in PubMed, Embase, and CNKI. The inclusion criteria were the taxane/vinorebine-based chemotherapy in patients with NSCLC and the evaluation of the clinical outcomes in relation to the expression of TUBB3. The clinical outcomes analyzed in this study included the overall response rate (ORR), overall survival (OS), and event-free survival (EFS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to assess the risk associated with the TUBB3 expression in the taxane/vinorebine-based chemotherapy. Results A total of 28 studies with 2401 NSCLC patients were qualified for this meta-analysis. We found that the positive or high level of TUBB3 expression was associated with a poorer ORR (OR = 0.24, 95% CI = 0.16–0.36, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|